China-based biopharmaceutical company Henlius (HKG: 2696) has released its financial report for the first quarter of 2023, showing a robust increase in revenues. As of March 31, 2023, the company reported revenues of RMB 995.7 million (USD 144.9 million), marking a 97.2% year-on-year (YOY) growth.
Sales Performance of Key Products
Henlius’s product Hanquyou (trastuzumab) contributed significantly to the revenue, generating RMB 538.6 million (USD 78.4 million) in sales within China, representing a 66.7% YOY increase. Another standout performer was the PD-1 inhibitor HaiSiZhuang (serplulimab), which brought in RMB 249.8 million (USD 36.3 million) in revenue, achieving a milestone with sales exceeding RMB 100 million in a single month for the first time in March.
Regulatory Approvals and Pipeline Updates
HaiSiZhuang has been approved in China for the treatment of microsatellite highly unstable (MSI-H) solid tumors, squamous non-small cell lung cancer, and small cell lung cancer. The drug is also awaiting regulatory decisions for its use in first-line esophageal squamous cell carcinoma (ESCC). Henlius continues to expand its international presence, advancing the overseas commercialization of its products, including HanSiZhuang, Hanquyou, HanLiKang, and biosimilar versions of adalimumab and bevacizumab.
Conclusion
The Q1 2023 financial report from Henlius demonstrates the company’s strong financial performance and the successful commercialization of its key products. With a promising pipeline and ongoing international expansion, Henlius is well-positioned to continue its growth trajectory in the biopharmaceutical industry.-Fineline Info & Tech
